A new trading day began on Friday, with Beam Therapeutics Inc (NASDAQ: BEAM) stock price up 3.71% from the previous day of trading, before settling in for the closing price of $17.25. BEAM’s price has ranged from $13.52 to $35.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43280.87% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -1.28%. With a float of $87.47 million, this company’s outstanding shares have now reached $100.56 million.
In an organization with 483 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.06%, operating margin of -677.47%, and the pretax margin is -609.18%.
Beam Therapeutics Inc (BEAM) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Beam Therapeutics Inc is 12.21%, while institutional ownership is 87.90%. The most recent insider transaction that took place on Apr 01 ’25, was worth 104,122. In this transaction Chief Legal Officer of this company sold 5,674 shares at a rate of $18.35, taking the stock ownership to the 117,294 shares. Before that another transaction happened on Apr 01 ’25, when Company’s CEO sold 30,663 for $18.35, making the entire transaction worth $562,684. This insider now owns 986,249 shares in total.
Beam Therapeutics Inc (BEAM) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.72% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Here are Beam Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.61, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.71 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.7 million. That was inferior than the volume of 2.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.19%. Additionally, its Average True Range was 1.47.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 20.09%, which indicates a significant decrease from 44.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.44% in the past 14 days, which was higher than the 85.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.82, while its 200-day Moving Average is $24.39. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $18.17. Second resistance stands at $18.45. The third major resistance level sits at $18.95. If the price goes on to break the first support level at $17.40, it is likely to go to the next support level at $16.90. Assuming the price breaks the second support level, the third support level stands at $16.62.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
With a market capitalization of 1.80 billion, the company has a total of 100,557K Shares Outstanding. Currently, annual sales are 63,520 K while annual income is -376,740 K. The company’s previous quarter sales were 7,470 K while its latest quarter income was -109,270 K.
